AbCellera Biologics Inc. (ABCL) Operating margin 2019–2025
AbCellera Biologics Inc. (ABCL) operating margin by fiscal year — reported operating income divided by reported revenue.
-289.0%FY2025 · since FY2019: -35.5% → -289.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -289.0% | +802.7 pp |
| FY2024 | -1091.7% | -467.9 pp |
| FY2023 | -623.8% | -668.4 pp |
| FY2022 | 44.6% | -9.9 pp |
| FY2021 | 54.5% | -12.4 pp |
| FY2020 | 66.9% | +102.4 pp |
| FY2019 | -35.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABCL financial trends
ABCL RevenueABCL Net incomeABCL Net marginABCL Gross profitABCL Gross marginABCL Operating incomeABCL Operating cash flowABCL Free cash flowABCL Capital expendituresABCL Return on equityABCL Stock buybacksABCL Dividends paidABCL Total assetsABCL Total liabilitiesABCL Shareholders’ equityABCL overview →